VivoSeq
Other

Donor

0

Pipeline Programs↗

8

Active Trials↗

1

Companies Involved↗

Donor is an early-stage landscape with 0 programs across 1 company. The most active players are Amgen.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

34

clinical trials

Completed22 · 65%
Recruiting6 · 18%
Terminated4 · 12%
Active, not recruiting2 · 6%

Clinical Trials

Trial Activity

34 trials

Blood Donor CVD 5000
Recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT03971669·150 enrolled
Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor Donation.
Recruiting·HHospices Civils de Lyon·N/A·NCT06047106·60 enrolled
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
Recruiting·UUniversity Health Network, Toronto·Phase 4·NCT07189377·20 enrolled
Lipid Characterisation of Plasma Microparticles in a Large Population of Healthy Donors
Recruiting·—·N/A·NCT06183632·150 enrolled
Donor-Derived Viral Specific T-cells (VSTs)
Recruiting·—·Phase 1/2·NCT02048332·750 enrolled
Phase 1 Study of Total Lymphoid Irradiation, Total Body Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+, T-cell and Recipient T Regulatory Cell Transfusion in Human Leukocyte Antigen Mismatched Living Donor Kidney Transplantation
Recruiting·SStanford University·Phase 1·NCT03943238·22 enrolled
Sucrosomial Iron and Iron Sulphate to Blood Donors
Active, not recruiting·UUppsala University Hospital·N/A·NCT05678647·120 enrolled
Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee
Active, not recruiting·VVanarix SA·Phase 1/2·NCT06897111·10 enrolled
Collection of Bone Marrow From Donors Treated With or Without Filgrastim
Completed·Children's Oncology Group·Phase 3·NCT01149096·13 enrolled
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Completed·—·Phase 2·NCT01403896·10 enrolled
Babesia Testing in Blood Donors
Completed·IImugen·Phase 3·NCT01528449·90,116 enrolled
TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT
Completed·UUniversity Health Network, Toronto·Phase 4·NCT01398982·93 enrolled
URMC Related Haplo-identical Donor BMT
Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
Completed·Amgen logoAmgen·N/A·NCT00115128·309 enrolled
Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV
Completed·National Institutes of Health Clinical Center (CC)·N/A·NCT00004846·30,000 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)